118 related articles for article (PubMed ID: 11271495)
41. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
42. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
[TBL] [Abstract][Full Text] [Related]
43. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.
Giocanti N; Sadri R; Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Favaudon V
Ann N Y Acad Sci; 1999; 886():180-2. PubMed ID: 10667214
[No Abstract] [Full Text] [Related]
44. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
45. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
[TBL] [Abstract][Full Text] [Related]
46. A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein.
Ratner N; Bloom GS; Brady ST
J Neurosci; 1998 Oct; 18(19):7717-26. PubMed ID: 9742142
[TBL] [Abstract][Full Text] [Related]
47. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
48. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Pennati M; Campbell AJ; Curto M; Binda M; Cheng Y; Wang LZ; Curtin N; Golding BT; Griffin RJ; Hardcastle IR; Henderson A; Zaffaroni N; Newell DR
Mol Cancer Ther; 2005 Sep; 4(9):1328-37. PubMed ID: 16170024
[TBL] [Abstract][Full Text] [Related]
49. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
50. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
[TBL] [Abstract][Full Text] [Related]
51. Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
Zhou Y; Guo YJ; Liu X; Mei YW
Neurol Res; 2009 Nov; 31(9):910-6. PubMed ID: 19138471
[TBL] [Abstract][Full Text] [Related]
52. [Effects of cyclin dependent protein kinase inhibitor olomoucine on the neuronal apoptosis after status epilepticus: experiment with rats].
Du XP; Sun MZ; Yu ZY; Chen HX; Tian DS; Xie MJ; Wang W
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(29):2025-9. PubMed ID: 17925171
[TBL] [Abstract][Full Text] [Related]
53. In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes.
Rypka M; Veselý J; Chmela Z; Riegrová D; Cervenková K; Havlícek L; Lemr K; Hanus J; Cerný B; Lukes J; Michalíková K
Xenobiotica; 2002 Nov; 32(11):1017-31. PubMed ID: 12487731
[TBL] [Abstract][Full Text] [Related]
54. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood.
Takeuchi S; Bartram CR; Seriu T; Miller CW; Tobler A; Janssen JW; Reiter A; Ludwig WD; Zimmermann M; Schwaller J
Blood; 1995 Jul; 86(2):755-60. PubMed ID: 7606004
[TBL] [Abstract][Full Text] [Related]
55. Proteome analysis of a human heptocellular carcinoma cell line, HCC-M: an update.
Ou K; Seow TK; Liang RC; Ong SE; Chung MC
Electrophoresis; 2001 Aug; 22(13):2804-11. PubMed ID: 11545412
[TBL] [Abstract][Full Text] [Related]
56. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
57. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Haesslein JL; Jullian N
Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
[TBL] [Abstract][Full Text] [Related]
59. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
